ライフサイエンスコーパス: anal cancer

1 with HIV infection have an elevated risk of anal cancer.

2 PV) 16 and 18 infections cause most cases of anal cancer.

3 y profile and may help to reduce the risk of anal cancer.

4 ce of anal HPV infections that contribute to anal cancer.

5 IV-1)-infected men are at increased risk for anal cancer.

6 ffect on local failure and colostomy rate in anal cancer.

7 usses the issues around screening to prevent anal cancer.

8 oplasia treatment to reduce the incidence of anal cancer.

9 als and recent studies on chemoradiation for anal cancer.

10 of intensity modulated radiation therapy for anal cancer.

11 icant role during posttreatment follow-up of anal cancer.

12 al adenocarcinoma, oropharyngeal cancer, and anal cancer.

13 vaccination and decrease in lifetime risk of anal cancer.

14 lysis to highlight discrepancies relevant to anal cancer.

15 life years, and lifetime risk of developing anal cancer.

16 used to record adverse events using PROs for anal cancer.

17 g men who have sex with men (MSM) and causes anal cancer.

18 -HPV infections, consistent with its role in anal cancer.

19 ximately 6-7 years prior to the diagnosis of anal cancer.

20 me a useful diagnostic tool in patients with anal cancer.

21 ablished prognostic factors in patients with anal cancer.

22 ponse evaluation after chemoradiotherapy for anal cancer.

23 o 90% of anal intraepithelial neoplasias and anal cancers.

24 maviruses (HPVs) cause a large proportion of anal cancers.

25 , 4.5% and 0.7%; lung cancer, 3.4% and 2.8%; anal cancer, 1.5% and 0.05%; colorectal cancer, 1.0% and

26 ial (37%), breast (31%), cervical (29%), and anal cancer (27%).

27 te ratios of 3.85 (95% CI, 2.32 to 6.37) for anal cancer, 6.68 (95% CI, 3.64 to 12.25) for anal intra

28 squamous intraepithelial lesions (HSIL) and anal cancer (AC) compared with HIV-uninfected women.

29 We compared incidence rates of anal cancer across four calendar periods: 1992-1996 (pre

30 emoradiation became the standard of care for anal cancer after the ACT I trial.

31 esent the results of a case-control study of anal cancer among HIV-infected people in Switzerland.

32 The high incidence of anal cancer among HIV-positive individuals must not be i

33 An increasing incidence of anal cancer among men suggests a need to better understa

34 ssary to identify men at the highest risk of anal cancer among those infected with high-risk HPV.

35 good accuracy in posttreatment evaluation of anal cancer and has a relevant impact on patient managem

36 Besides anal cancer and Hodgkin disease, the cohort studies have

37 All patients displayed squamous anal cancer and were treated with MMC alone or MMC plus

38 Most squamous cell anal cancers and precancerous lesions are attributed to

39 study strengthens evidence that lung cancer, anal cancer, and myeloma are diagnosed at modestly young

40 ar, no history of genital warts or penile or anal cancer, and no current diagnosis of a sexually tran

41 esophageal, cervical, prostate, and possibly anal cancers; and since the 1990s for bone/joint and end

42 de anal intraepithelial neoplasia to prevent anal cancer are warranted.

43 Most anal cancers are attributable to persistent human papill

44 llomavirus (HPV) is causally associated with anal cancer, as HPV DNA is detected in up to 90% of anal

45 ity is relatively common before diagnosis of anal cancer but rare for other HPV-related anogenital ca

46 tant at an early stage of the development of anal cancer, but that the neoplastic process becomes irr

47 ent for HGAIN decreased the lifetime risk of anal cancer by 63% compared with no vaccination.

48 high-grade anal intraepithelial neoplasia or anal cancer by history or by screening cytology or histo

49 A majority of anal cancer cases (73%) were men who have sex with men.

50 A case-control study that included 59 anal cancer cases and 295 individually matched controls

51 papillomavirus (HPV) vaccination may prevent anal cancer caused by vaccine types.

52 igh-resolution anoscopy-guided ablation) and anal cancer (chemoradiation and possibly intensity-modul

53 seven of 24 individuals) who later developed anal cancer compared with 0.6% of controls (four of 718

54 ) are at increased risk of HPV infection and anal cancer compared with HIV-negative men.

55 appeared to be strongest 6-7 years prior to anal cancer diagnosis (OR for <200 vs. >/=500 cells/muL

56 The risk of anal cancer due to high-risk human papillomavirus (HR-HP

57 We report the case of a 66-year-old anal cancer female patient presenting with an asymptomat

58 us (HIV)-infected women are at high risk for anal cancer, few data have been published on prevalence

59 l cancer since no questionnaire specific for anal cancer has been developed.

60 The incidence of anal cancer has been increasing among U.S. women, yet fe

61 Recent studies show that the incidence of anal cancer has increased since the introduction of high

62 with increased cancer-specific mortality for anal cancer, Hodgkin lymphoma, or diffuse large B-cell l

63 an papillomavirus-related cancers, including anal cancer (HR, 2.77; 95% CI, 1.29-5.96) and female gen

64 ention of human papillomavirus (HPV)-induced anal cancer in high-risk populations such as human immun

65 Treatment options for anal dysplasia and anal cancer in HIV-infected individuals are expanding an

66 that in the general population, the risk of anal cancer in HIV-infected patients is still extremely

67 In the United States, anal cancer in men who have sex with men (MSM) is more c

68 5.9 (95% confidence interval, 3.4-10.3) for anal cancer in men.

69 of 30 and may explain the high incidence of anal cancer in MSM.

70 ination may be useful for early detection of anal cancer in these populations.

71 te intensity modulated radiation therapy for anal cancer, in an effort to reduce acute and long-term

72 ulation, used Poisson regression to evaluate anal cancer incidence among subgroups of people with HIV

73 Anal cancer incidence did not correlate with HIV-1 antib

74 ted standardized incidence ratios to compare anal cancer incidence in people with HIV infection with

75 Conclusion Anal cancer incidence is markedly elevated among people

76 tiretroviral therapy to HIV-infected people, anal cancer incidence may start to decline.

77 follow-up between 1996 and 2007, we compared anal cancer incidence rates among 34 189 HIV-infected (5

78 Among men, the unadjusted anal cancer incidence rates per 100 000 person-years wer

79 Anal cancer incidence was highest among men who have sex

80 lts Among 447,953 people with HIV infection, anal cancer incidence was much higher than in the genera

81 Risk of anal cancer increased after 1995 (RH = 2.9).

82 Only the relative incidence of anal cancer increased over time.

83 lications in the areas of colon, rectal, and anal cancers; inflammatory bowel disease; incontinence;

84 e of PVOD in the French population that have anal cancer is 3.9 of 1000 patients, which is much highe

85 The majority of anal cancer is associated with human papillomavirus (HPV

86 Like cervical cancer, anal cancer is associated with human papillomavirus (HPV

87 Anal cancer is caused by human papillomavirus (HPV), yet

88 Anal cancer is common among people infected with human i

89 infections are common, and the incidence of anal cancer is high in HIV-infected men who have sex wit

90 One of the groups at highest risk of anal cancer is homosexual and bisexual men.

91 Although the primary cause of anal cancer is human papillomavirus (HPV) infection in t

92 The rate of anal cancer is increasing among both women and men, part

93 Human papillomavirus (HPV)-associated anal cancer is increasing in prevalence and is more comm

94 he use of MMC in a definitive CR regimen for anal cancer is justified, particularly in patients with

95 Anal cancer is more common in women than in men, yet lit

96 The role of cisplatin in anal cancer is not completely clear, although an ongoing

97 Anal cancer is one of the most common cancers affecting

98 As anal cancer is potentially preventable, these important

99 es occurring in the HIV-positive population, anal cancer is potentially preventable, using methods si

100 omavirus (HPV), primarily HPV type 16 or 18, anal cancer is preceded by high-grade anal intraepitheli

101 incidence of human papillomavirus-associated anal cancer is unacceptably high among HIV-positive men

102 ho have sex with men, are at excess risk for anal cancer, it has been difficult to disentangle the in

103 continue to have high rates of cervical and anal cancer, it is important to continue screening effor

104 ncies, some related to known infections (eg, anal cancer, Kaposi sarcoma) and others unrelated (eg, m

105 Groups with high cumulative incidence of anal cancer may benefit from screening.

106 gnosis of lung (median, 50 vs. 54 years) and anal cancer (median, 42 vs. 45 years) were significantly

107 nt smoking was significantly associated with anal cancer (odds ratio (OR) = 2.59, 95% confidence inte

108 E6 antibodies, apart from anti-HPV58 E6 and anal cancer (OR, 6.8; 95% CI, 1.4 to 33.1).

109 cART appears to have no preventive effect on anal cancer, particularly in MSM.

110 h for reducing treatment-related toxicity in anal cancer patients.

111 drivalent HPV vaccine (qHPV) reduces risk of anal cancer/precancerous lesions in young men who have s

112 o have sex with men (MSM) without history of anal cancer/precancerous lesions.

113 Cytology screening can detect the anal cancer precursor, anal intraepithelial neoplasia (A

114 The anal cancer precursor, high-grade squamous intraepitheli

115 le and clinically relevant methods to detect anal cancer precursors.

116 HIV-infected women had an anal cancer rate of 30/100 000 person-years, and no case

117 Anal cancer rates are higher for human immunodeficiency

118 Anal cancer rates were substantially higher for HIV-infe

119 Anal cancer rates were substantially higher for HIV-infe

120 With the gradual increase of anal cancer rates, there is a growing need to establish

121 Guidelines for anal cancer recommend assessment of response at 6-12 wee

122 vention of anal intraepithelial neoplasia or anal cancer related to infection with HPV-6, 11, 16, or

123 Anal cancer remains rare (incidence of about 1.5 per 100

124 They demonstrate that anal cancer risk is increased in association with a low

125 human papillomavirus type 16 protein E6 and anal cancer risk, highlighting the role of this viral on

126 appear to be important in reducing long-term anal cancer risks.

127 pational exposure of healthcare workers; (5) anal cancer screening among men who have sex with men (M

128 ers could help refine clinical approaches to anal cancer screening and prevention for the HIV-infecte

129 All HIV-infected adults should be offered anal cancer screening as part of clinical care at specia

130 ological study to evaluate whether access to anal cancer screening programs may help improve patient

131 sidered when selecting the best approach for anal cancer screening programs.

132 Anal cancer screening should be considered for HIV-posit

133 Data are insufficient to recommend routine anal cancer screening with anal cytology in persons livi

134 tertiary dermatological referral center for anal cancer screening.

135 eased risk for HG-AIN+ and should be offered anal cancer screening.

136 detection is a potentially relevant tool for anal cancer screening.

137 o -1.86; P < .001), whereas the incidence of anal cancer significantly increased (APC, 4.42; 95% CI,

138 to use in clinical research and practice for anal cancer since no questionnaire specific for anal can

139 o reduction in the incidence of cervical and anal cancer since the introduction of highly active anti

140 and substantially elevated risks for second anal cancer (SIR = 120.50) and Kaposi's sarcoma (SIR = 1

141 n's disease (SIR = 2.5; 95% CI 1.5-3.9), and anal cancer (SIR = 24.2 95% CI 13.5-39.9).

142 d cancer survival time with HAART use, while anal cancer survival may have been slightly decreased (R

143 consequence of staging misclassification in anal cancer that we have termed reduced prognostic discr

144 In US men, the incidence of anal cancer, the primary cause of which is human papillo

145 The results of our trial--the largest in anal cancer to date--show that fluorouracil and mitomyci

146 s, and estimated the cumulative incidence of anal cancer to measure absolute risk.

147 e in longitudinal follow-up of patients with anal cancer treated with (chemo)radiation, the EORTC-QLQ

148 etabolic tumor volume (MTV) in patients with anal cancer treated with definitive chemoradiotherapy.

149 Domains and codes relevant to anal cancer treatment were selected from interviews to i

150 other HPV-related cancers (e.g. cervical and anal cancer), trends over time do not appear to be influ

151 clear, although an ongoing randomized trial (Anal Cancer Trial II) may help clarify the role of cispl

152 and clinician reporting instruments used in anal cancer trials including radiation treatment.

153 An excess in anal cancer was observed but did not appear to be associ

154 In the USA, more than 7200 new cases of anal cancer were diagnosed in 2014 with incidence rising

155 Patients with anal cancer who underwent PET imaging for pretreatment s

156 ly been questioned, while the association of anal cancer with AIDS in both males and females is more

157 the general population had an excess risk of anal cancer, with SIRs of 109.8 (95% CI, 84.6 to 140.3),